🎥 Inga Mandac-Smoljanovic outlines the factors that affect the dose of ibrutinib administered in patients with CLL, highlighting the importance of considering comorbidities & concomitant medications when selecting a dose:

👉 buff.ly/Rs2rluB 👈

#iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky

Want to hear about the development of rocbrutinib, a 4th-generation BTK inhibitor, as a potential therapeutic option for BTKi-resistant CLL?🩸

Watch our interview with Britten Gordon from #iwCLL2025:

🎥 buff.ly/eKQamE2

#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky

🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:

👉 buff.ly/paPH5vx 👈

#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky

It was great to catch up with @drmdavids.bsky.social of @danafarber.bsky.social at #iwCLL2025!🎥

Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:

👉 buff.ly/aouDK9h

#CLLsm

🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies:

👉 buff.ly/BKMPQGT 👈

#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky

The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉

We recently had the pleasure of speaking to Helen Parry to find out more about the study:

🎥 buff.ly/j1K0VV8

#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc

It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings.

Watch the interview here:

🎥 buff.ly/sZGLLe2

#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

How should physicians approach the management of patients with CLL who relapse following treatment with a triplet regimen? 💭🩸

Jacob Soumerai discussed this in a recent interview:

🎥 buff.ly/6qCplqB

#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky

🎥 Moritz Fürstenau comments on the optimal duration of time-limited BTK inhibitor plus BCL2 inhibitor combination therapy in CLL:

👉 buff.ly/BiuqDZd 👈

#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky

🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:

👉 buff.ly/rBWUBYh 👈

#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky

We recently spoke with Krzysztof Jamroziak, who provided valuable insight into the current role of MRD in CLL, highlighting technical aspects and its clinical significance.

Click here to check out the interview:

🎥 buff.ly/20uHc4O

#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky

Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸

Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:

🎥 buff.ly/AnTQebz

#CARTCell #ImmunoOnc #CLLsm #Leusm

At #iwCLL2025 last week, we had the pleasure of speaking with Kerry Rogers of @osuhematology.bsky.social to hear about the management of patients with double-refractory CLL.🩸

Watch the interview here:

🎥 buff.ly/ZwOkLWw

#CLLsm #Leusm #Leukemia #HemOnc

It's our first day onsite at #iwCLL2025 and we can't wait for two jam-packed days of expert interviews about all things CLL!🩸

Keep an eye on our site over the coming weeks for our exclusive coverage from the event.🎥

👉VJHemOnc.com

#CLLsm #Leusm #Leukemia #BloodSky #MedSky #HemeSky #HemOnc